Literature DB >> 20544848

Colorectal cancers show distinct mutation spectra in members of the canonical WNT signaling pathway according to their anatomical location and type of genetic instability.

Cristina Albuquerque1, Célia Baltazar, Bruno Filipe, Filipa Penha, Teresa Pereira, Ron Smits, Marília Cravo, Pedro Lage, Paulo Fidalgo, Isabel Claro, Paula Rodrigues, Isabel Veiga, José Silva Ramos, Isabel Fonseca, Carlos Nobre Leitão, Riccardo Fodde.   

Abstract

It is unclear whether the mutation spectra in WNT genes vary among distinct types of colorectal tumors. We have analyzed mutations in specific WNT genes in a cohort of 52 colorectal tumors and performed a meta-analysis of previous studies. Notably, significant differences were found among the mutation spectra. We have previously shown that in familial adenomatous polyposis, APC somatic mutations are selected to provide the "just-right" level of WNT signaling for tumor formation. Here, we found that APC mutations encompassing at least two beta-catenin down-regulating motifs (20 a.a. repeats) are significantly more frequent in microsatellite unstable (MSI-H) than in microsatellite stable (MSS) tumors where truncations retaining less than two repeats are more frequent (P = 0.0009). Moreover, in cases where both APC hits are detected, selection for mutations retaining a cumulative number of two 20 a.a. repeats became apparent in MSI-H tumors (P = 0.001). This type of mutations were also more frequent in proximal versus distal colonic tumors, regardless of MSI status (P = 0.0008). Among MSI-H tumors, CTNNB1 mutations were significantly more frequent in HNPCC than in sporadic lesions (28% versus 6%, P < 10-6) and were preferentially detected in the proximal colon, independently of MSI status (P = 0.017). In conclusion, the observed spectra of WNT gene mutations in colorectal tumors are likely the result from selection of specific levels of beta-catenin signaling, optimal for tumor formation in the context of specific anatomical locations and forms of genetic instability. We suggest that this may underlie the preferential location of MMR deficient tumors in the proximal colon.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20544848     DOI: 10.1002/gcc.20786

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  26 in total

1.  Familial colorectal cancer type X syndrome: two distinct molecular entities?

Authors:  Inês Francisco; Cristina Albuquerque; Pedro Lage; Hélio Belo; Inês Vitoriano; Bruno Filipe; Isabel Claro; Sara Ferreira; Paula Rodrigues; Paula Chaves; Carlos Nobre Leitão; António Dias Pereira
Journal:  Fam Cancer       Date:  2011-12       Impact factor: 2.375

2.  Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.

Authors:  Jonathan M Loree; Allan A L Pereira; Michael Lam; Alexandra N Willauer; Kanwal Raghav; Arvind Dasari; Van K Morris; Shailesh Advani; David G Menter; Cathy Eng; Kenna Shaw; Russell Broaddus; Mark J Routbort; Yusha Liu; Jeffrey S Morris; Rajyalakshmi Luthra; Funda Meric-Bernstam; Michael J Overman; Dipen Maru; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2017-11-27       Impact factor: 12.531

Review 3.  The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening.

Authors:  William M Grady; Sanford D Markowitz
Journal:  Dig Dis Sci       Date:  2014-12-10       Impact factor: 3.199

4.  Comprehensive site-specific whole genome profiling of stromal and epithelial colonic gene signatures in human sigmoid colon and rectal tissue.

Authors:  Jason M Knight; Eunji Kim; Ivan Ivanov; Laurie A Davidson; Jennifer S Goldsby; Meredith A J Hullar; Timothy W Randolph; Andrew M Kaz; Lisa Levy; Johanna W Lampe; Robert S Chapkin
Journal:  Physiol Genomics       Date:  2016-07-08       Impact factor: 3.107

5.  MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes.

Authors:  Lawrence A Donehower; Chad J Creighton; Nikolaus Schultz; Eve Shinbrot; Kyle Chang; Preethi H Gunaratne; Donna Muzny; Chris Sander; Stanley R Hamilton; Richard A Gibbs; David Wheeler
Journal:  J Pathol       Date:  2013-01       Impact factor: 7.996

6.  Promoter methylation of Wnt antagonists DKK1 and SFRP1 is associated with opposing tumor subtypes in two large populations of colorectal cancer patients.

Authors:  James B Rawson; Michael Manno; Miralem Mrkonjic; Darshana Daftary; Elizabeth Dicks; Daniel D Buchanan; H Banfield Younghusband; Patrick S Parfrey; Joanne P Young; Aaron Pollett; Roger C Green; Steven Gallinger; John R McLaughlin; Julia A Knight; Bharati Bapat
Journal:  Carcinogenesis       Date:  2011-02-08       Impact factor: 4.944

7.  Caffeinated and decaffeinated coffee and tea intakes and risk of colorectal cancer in a large prospective study.

Authors:  Rashmi Sinha; Amanda J Cross; Carrie R Daniel; Barry I Graubard; Jennifer W Wu; Albert R Hollenbeck; Marc J Gunter; Yikyung Park; Neal D Freedman
Journal:  Am J Clin Nutr       Date:  2012-06-13       Impact factor: 7.045

8.  Evaluation of tumor suppressor gene expressions and aberrant methylation in the colon of cancer-induced rats: a pilot study.

Authors:  Veronika Polakova Vymetalkova; Luca Vannucci; Vlasta Korenkova; Pavel Prochazka; Jana Slyskova; Ludmila Vodickova; Vendula Rusnakova; Ludovit Bielik; Monika Burocziova; Pavel Rossmann; Pavel Vodicka
Journal:  Mol Biol Rep       Date:  2013-09-25       Impact factor: 2.316

9.  Associations between circulating 1,25(OH)₂D concentration and odds of metachronous colorectal adenoma.

Authors:  Elizabeth A Hibler; Christine L Sardo Molmenti; Peter Lance; Peter W Jurutka; Elizabeth T Jacobs
Journal:  Cancer Causes Control       Date:  2014-04-16       Impact factor: 2.506

10.  Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer.

Authors:  Lukas E Dow; Kevin P O'Rourke; Janelle Simon; Darjus F Tschaharganeh; Johan H van Es; Hans Clevers; Scott W Lowe
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.